MX2011001170A - Derivados de benzoimidazol e inhibidores de glucogeno sintasa cinasa 3-beta que contienen los mismos. - Google Patents

Derivados de benzoimidazol e inhibidores de glucogeno sintasa cinasa 3-beta que contienen los mismos.

Info

Publication number
MX2011001170A
MX2011001170A MX2011001170A MX2011001170A MX2011001170A MX 2011001170 A MX2011001170 A MX 2011001170A MX 2011001170 A MX2011001170 A MX 2011001170A MX 2011001170 A MX2011001170 A MX 2011001170A MX 2011001170 A MX2011001170 A MX 2011001170A
Authority
MX
Mexico
Prior art keywords
benzo
imidazole
hydroxy
thiophen
carboxamide
Prior art date
Application number
MX2011001170A
Other languages
English (en)
Spanish (es)
Inventor
Mitsuaki Ohtani
Yingfu Li
Ryuji Ohsawa
Yo Matsuo
Shoji Hisada
Joel R Walker
David M Jenkins
Feryan Ahmed
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2011001170A publication Critical patent/MX2011001170A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2011001170A 2008-07-30 2009-07-30 Derivados de benzoimidazol e inhibidores de glucogeno sintasa cinasa 3-beta que contienen los mismos. MX2011001170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8477008P 2008-07-30 2008-07-30
PCT/US2009/052225 WO2010014794A1 (en) 2008-07-30 2009-07-30 Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same

Publications (1)

Publication Number Publication Date
MX2011001170A true MX2011001170A (es) 2011-04-05

Family

ID=41610727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011001170A MX2011001170A (es) 2008-07-30 2009-07-30 Derivados de benzoimidazol e inhibidores de glucogeno sintasa cinasa 3-beta que contienen los mismos.

Country Status (14)

Country Link
US (1) US20110190351A1 (enExample)
EP (1) EP2309855A4 (enExample)
JP (1) JP2011529903A (enExample)
KR (1) KR20110040958A (enExample)
CN (1) CN102170785A (enExample)
AU (1) AU2009276548A1 (enExample)
BR (1) BRPI0916726A2 (enExample)
CA (1) CA2732280A1 (enExample)
CO (1) CO6351688A2 (enExample)
IL (1) IL210863A0 (enExample)
MX (1) MX2011001170A (enExample)
RU (1) RU2011107227A (enExample)
WO (1) WO2010014794A1 (enExample)
ZA (1) ZA201101160B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362268B2 (en) 2008-05-30 2013-01-29 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
CN101619058A (zh) * 2009-01-08 2010-01-06 上海交通大学 一种苯并咪唑-4-酰胺型衍生物
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9815787B2 (en) * 2013-12-12 2017-11-14 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
CN105461722B (zh) * 2014-09-04 2019-05-10 欣凯医药化工中间体(上海)有限公司 一种脱氮嘌呤类化合物及其衍生物及其制备方法和应用
WO2016133160A1 (ja) * 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
US20240132485A1 (en) * 2020-10-16 2024-04-25 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
KR20240008807A (ko) * 2022-07-12 2024-01-19 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178413A1 (en) * 1984-08-17 1986-04-23 Beecham Group Plc Benzimidazoles
FR2699816B1 (fr) * 1992-12-30 1995-03-03 Oreal Compositions tinctoriales pour fibres kératiniques à base de paraphénylènediamines, de métaphénylènediamines et de dérivés du benzimidazole, et procédé de teinture les mettant en Óoeuvre.
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
JP2006515013A (ja) * 2003-01-23 2006-05-18 クリスタルジェノミクス、インコーポレイテッド グリコーゲン合成酵素キナーゼ3β活性抑制剤、組成物及びその製造方法
AU2009310310A1 (en) * 2008-10-30 2010-05-06 Oncotherapy Science, Inc. 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK inhibitors containing the same
EP2358365A4 (en) * 2008-11-20 2012-05-30 Oncotherapy Science Inc GLYCOGEN SYNTHASE KINASE 3 BETA HEMMER WITH 7-HYDROXY BENZOIMIDAZOLE-4-YL METHANONE DERIVATIVES

Also Published As

Publication number Publication date
CO6351688A2 (es) 2011-12-20
EP2309855A1 (en) 2011-04-20
CA2732280A1 (en) 2010-02-04
WO2010014794A1 (en) 2010-02-04
RU2011107227A (ru) 2012-09-10
US20110190351A1 (en) 2011-08-04
BRPI0916726A2 (pt) 2017-07-04
EP2309855A4 (en) 2012-06-27
KR20110040958A (ko) 2011-04-20
JP2011529903A (ja) 2011-12-15
CN102170785A (zh) 2011-08-31
ZA201101160B (en) 2011-10-26
AU2009276548A1 (en) 2010-02-04
IL210863A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
US20110190351A1 (en) Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same
US9622991B2 (en) Hematopoietic growth factor mimetic small molecule compounds and their uses
AU781506B2 (en) Integrin expression inhibitors
AU2007248341B2 (en) Benzimidazole modulators of VR1
AU2005299112B2 (en) Heterocyclic carbonyl compounds
US20030087902A1 (en) Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
CN101155783B (zh) 吡唑类化合物
ES2272749T3 (es) Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
JP2011529903A5 (enExample)
US20080312435A1 (en) Imine Compound
OA11450A (en) N-Ä(substituted five-membered di-or triaza diunsaturated ring)carbonylÜ guanidine derivatives for the treatment of ischemia.
WO2011099832A2 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AU2007333194A1 (en) LXR and FXR modulators
AU2004207740A1 (en) Indole-derivative modulators of steroid hormone nuclear receptors
WO2004052280A2 (en) Anti-angiogenic compounds and their use in cancer treatment
JP2005501856A5 (enExample)
WO2005090328A1 (ja) 複素環化合物およびその用途
JP2010533725A (ja) ヒスタミン‐3(h3)受容体としてのアミノアルキルアゾール化合物
CA2577818A1 (en) New heterocyclic amides
JP2002522423A (ja) α1A作動薬としてのイミダゾール及び関連化合物
JP2012509249A (ja) 7−ヒドロキシ−ベンゾイミダゾール−4−イル−メタノン誘導体を含むグリコーゲン合成酵素キナーゼ−3ベータ阻害剤
US10689354B2 (en) Aminoazole derivative
US11912687B2 (en) 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US11136312B2 (en) 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
CN110105286A (zh) 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途